Purpose: Resistance to platinum chemotherapy remains a significant problem in ovarian carcinoma.

Early studies showed antitumor activity, especially against malignant melanoma and ovarian carcinoma.

Six of these genes were not previously implicated in inherited ovarian carcinoma.

However, its clinical significance in human ovarian carcinoma has been uncertain until recently.

Distant metastases are unusual at presentation and during the course of ovarian carcinoma.

The prognostic value of Mucin-1 expression in ovarian carcinoma remains uncertain.

We found that deregulation of miR-506 in ovarian carcinoma promotes an aggressive phenotype.

Aims: Multidrug resistance is a major impediment in chemotherapeutic treatment of ovarian carcinoma patients.

Of these hens, 8 animals were thought grossly to have ovarian carcinoma and ascites.

Participants: Thirty-four women undergoing debulking surgery for ovarian carcinoma participated.

Small-cell lung cancer and ovarian carcinoma are logical tumour types to pursue with topotecan.

Background: The dose intensity of chemotherapy for patients with ovarian carcinoma remains a controversial issue.

In effect, there is a known dose-response relationship in ovarian carcinoma, especially with alkylating agents.

Epidemiological and cell culture studies indicate that ovarian carcinoma growth is dependent on estrogen stimulation.

More patients with ovarian carcinoma carry cancer-predisposing mutations and in more genes than previously appreciated.

The activity of the antiestrogen tamoxifen was evaluated in 23 patients with epithelial ovarian carcinoma.